中文

Overview

Performance

Distributions

Growth of $10,000

Holdings

Fund Documents

Overview

Investment Strategy:

KURE tracks the MSCI China All Shares Health Care 10/40 Index, providing targeted exposure to Chinese companies engaged in the health care sector. The Index is a free float adjusted market capitalization weighted index that includes companies listed in Mainland China, Hong Kong and United States. Issuers eligible for inclusion must be classified under the Global Industry Classification Standard as engaged in the healthcare sector. The issuers included in the Underlying Index may include small-cap, mid-cap and large-cap companies.

China Health Care Sector Highlights:

  • China is one of the fastest growing major healthcare markets in the world with a ten-year compound annual growth rate of 13%, compared to just 3% in the United States and 2% in Japan1.
  • China is the second largest healthcare market globally with total healthcare expenditures reaching $1.1 trillion in 2019, increasing at an average annual growth rate of 11% over the last 5 years2.
  • There is still opportunity for considerable growth in China’s healthcare market with per capita health spending at just $501, compared to an average of over $5,700 for the world’s top eight healthcare markets3.
  • China’s aging population, rising incomes and increasing urbanization may provide a sustained catalyst for growth in China’s healthcare sector.

KURE features:

  • Exposure to Chinese companies listed in the Mainland, Hong Kong and United States that are involved in the healthcare industry, specifically: patent and generic pharmaceuticals, hospital administration, biotechnology, medical equipment production, healthcare IT, and traditional Chinese medicine.
  • Exposure to companies that benefit from China’s growing middle class and aging population.
  • Access to leading Chinese pharmaceutical companies which have been recipients of favorable policy and market conditions for research and development and the invention of new medicines and devices.

1.) Major healthcare markets defined as top five global markets by the World Health Organization. Data from the World Health Organization, last updated on 4/7/2020. Retrieved 9/30/2021.
2.) China Briefing, “China’s Healthcare Industry – Opportunities in Telemedicine and Digital Healthcare”, Jul. 31, 2020, Retrieved 9/30/2021.
3.) Data from the World Health Organization, last updated on 4/7/2020. Retrieved 9/30/2021.

Fund Details

Data as of 09/28/2023
Ticker KURE
Primary Exchange NYSE
CUSIP 500767835
ISIN US5007678353
Net Assets $67,008,314
Total Annual Fund Operating Expense (Gross) 0.79%
Total Annual Fund Operating Expense (Net) 0.65%*
Inception Date 1/31/2018
Distribution Frequency Annual

Trending Funds:

KLXY

KraneShares Global Luxury Index ETF

KSEA

KraneShares Rockefeller℠ Ocean Engagement ETF

KLIP

KraneShares China Internet & Covered Call Strategy ETF

KEM

KraneShares Dynamic Emerging Markets Strategy ETF

Explore All Products

Premium Discount Chart

Daily Performance

Data as of 09/28/2023
Daily Net Asset Value (NAV) and Market Price
NAV $17.87
NAV Daily Change -0.78%
Market Price $17.82
Market Price Daily Change -0.17%
30 Day Median Bid/Ask Spread
1.03%
The ETF’s 30 Day Median Bid-Ask Spread is calculated by identifying the ETF’s national best bid and national best offer ("NBBO") as of the end of each 10 second interval during each trading day of the last 30 calendar days and dividing the difference between each such bid and offer by the midpoint of the NBBO. The median of those values is identified and that value is expressed as a percentage rounded to the nearest hundredth.

Performance History

Cumulative %
Data as of: 08/31/2023
Fund NAV Closing Price Index
1 Month -7.15% -8.26% -7.15%
3 Month -7.58% -7.63% -7.71%
6 Month -17.93% -18.60% -17.89%
YTD -17.24% -17.95% -16.76%
Since Inception -18.47% -18.98% -15.29%
Avg Annualized %
Data as of month end: 08/31/2023
Fund NAV Closing Price Index
1 Year -14.31% -14.26% -13.84%
3 Year -17.18% -17.46% -16.55%
5 Year -2.80% -3.34% -1.91%
Since Inception -3.59% -3.70% -2.93%
Avg Annualized %
Data as of quarter end: 06/30/2023
Fund NAV Closing Price Index
1 Year -22.24% -22.89% -21.81%
3 Year -13.27% -13.42% -12.54%
5 Year -5.16% -5.03% -4.21%
Since Inception -3.30% -3.34% -2.61%

*Fee waivers are contractual and in effect until August 1, 2024

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted.

Ex-Date Record Date Payable Date Amount

Distribution History

2022 Distributions
Ex-Date Record Date Payable Date Amount
12/28/2022 12/29/2022 12/30/2022 0.010399
2021 Distributions
Ex-Date Record Date Payable Date Amount
12/29/2021 12/30/2021 12/31/2021 4.053537
2020 Distributions
Ex-Date Record Date Payable Date Amount
12/29/2020 12/30/2020 12/31/2020 0.000109
2019 Distributions
Ex-Date Record Date Payable Date Amount
12/27/2019 12/30/2019 12/31/2019 0.057325

View More

2018 Distributions
Ex-Date Record Date Payable Date Amount
12/24/2018 12/24/2018 12/28/2018 0.039344
12/26/2018 12/27/2018 12/28/2018 0.036607

Topics:

Growth of $10,000

Data as of 09/28/2023

The Growth of $10,000 chart reflects an initial investment of $10,000 on the day prior to the selected time period and assumes reinvestment of dividends and capital gains. For the growth of $10,000 chart since inception, the initial investment of $10,000 is instead made on the inception date of the Fund. Fund expenses, including management fees and other expenses were deducted. The growth of a $10,000 investment in the fund is hypothetical and for illustration purposes only.

Top 10 Holdings

Data as of 09/29/2023 Full Holdings .CSV
Rank Name % of Net Assets Ticker Identifier Shares Held Market Value($)
1 WUXI BIOLOGICS CAYMAN INC 9.01% 2269 KYG970081173 1,036,135 6,039,386
2 SHENZHEN MINDR-A 6.34% 300760 CNE100003G67 114,855 4,253,375
3 JIANGSU HENGRU-A 5.58% 600276 CNE0000014W7 606,428 3,740,572
4 BEIGENE LTD 4.48% 6160 KYG1146Y1017 218,818 3,006,291
5 WUXI APPTEC CO LTD-A 4.30% 603259 CNE1000031K4 243,920 2,885,225
6 AIER EYE HSPTL-A 3.26% 300015 CNE100000GR6 886,714 2,187,043
7 CSPC PHARMACEUTI 3.09% 1093 HK1093012172 2,828,889 2,073,306
8 ZHANGZHOU PIEN-A 3.03% 600436 CNE000001F21 53,834 2,033,511
9 INNOVENT BIOLOGICS INC 2.67% 1801 KYG4818G1010 366,000 1,787,509
10 CHONGQING ZHIF-A 2.27% 300122 CNE100000V20 227,972 1,522,890

Holdings are subject to change.

Fund Documents

©2023 Krane Funds Advisors, LLC
280 Park Avenue, 32nd Floor, New York, NY 10017

Carefully consider the Funds’ investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Funds’ full and summary prospectus, which may be obtained by visiting: www.kraneshares.com. Read the prospectus carefully before investing.

Risk Disclosures:

Investing involves risk, including possible loss of principal. There can be no assurance that a Fund will achieve its stated objectives. Indices are unmanaged and do not include the effect of fees. One cannot invest directly in an index.

This information should not be relied upon as research, investment advice, or a recommendation regarding any products, strategies, or any security in particular. This material is strictly for illustrative, educational, or informational purposes and is subject to change. Certain content represents an assessment of the market environment at a specific time and is not intended to be a forecast of future events or a guarantee of future results; material is as of the dates noted and is subject to change without notice.

The Fund may invest in derivatives, which are often more volatile than other investments and may magnify the Fund’s gains or losses. A derivative (i.e., futures/forward contracts, swaps, and options) is a contract that derives its value from the performance of an underlying asset. The primary risk of derivatives is that changes in the asset’s market value and the derivative may not be proportionate, and some derivatives can have the potential for unlimited losses. Derivatives are also subject to liquidity and counterparty risk. The Fund is subject to liquidity risk, meaning that certain investments may become difficult to purchase or sell at a reasonable time and price. If a transaction for these securities is large, it may not be possible to initiate, which may cause the Fund to suffer losses. Counterparty risk is the risk of loss in the event that the counterparty to an agreement fails to make required payments or otherwise comply with the terms of the derivative.

The ability of the Fund to achieve its respective investment objectives is dependent, in part, on the continuous availability of A Shares and the ability to obtain, if necessary, additional A Shares quota. If the Fund is unable to obtain sufficient exposure to limited availability of A Share quota, the Fund could seek exposure to the component securities of the Underlying Index by investment in other types of securities. The Fund is subject to political, social or economic instability within China which may cause decline in value. Emerging markets involve heightened risk related to the same factors as well as increase volatility and lower trading volume. Fluctuations in currency of foreign countries may have an adverse effect to domestic currency values. The Fund may invest in Initial Public Offerings (IPOs). Securities issued in IPOs have no trading history, and information about the companies may be available for very limited periods. In addition, the prices of securities sold in IPOs may be highly volatile. In addition, as the Fund increases in size, the impact of IPOs on the Fund’s performance will generally decrease.

Narrowly focused investments typically exhibit higher volatility. The Fund’s assets are expected to be concentrated in a sector, industry, market, or group of concentrations to the extent that the Underlying Index has such concentrations. The securities or futures in that concentration could react similarly to market developments. Thus, the Fund is subject to loss due to adverse occurrences that affect that concentration. In addition to the normal risks associated with investing, investments in smaller companies typically exhibit higher volatility. KURE is non-diversified.

ETF shares are bought and sold on an exchange at market price (not NAV) and are not individually redeemed from the Fund. However, shares may be redeemed at NAV directly by certain authorized broker-dealers (Authorized Participants) in very large creation/redemption units. The returns shown do not represent the returns you would receive if you traded shares at other times. Shares may trade at a premium or discount to their NAV in the secondary market. Brokerage commissions will reduce returns. Beginning 12/23/2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn't available, the midpoint between the national best bid and national best offer ("NBBO") as of the time the ETF calculates the current NAV per share. Prior to that date, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time.

The KraneShares ETFs and KFA Funds ETFs are distributed by SEI Investments Distribution Company (SIDCO), 1 Freedom Valley Drive, Oaks, PA 19456, which is not affiliated with Krane Funds Advisors, LLC, the Investment Adviser for the Funds, or any sub-advisers for the Funds.

Privacy Policy

Whistleblower Policy

You are now leaving KraneShares.com

Hyperlinks on this website are provided as a convenience and we disclaim any responsibility for information, services or products found on the websites linked hereto.

Click here to continue

Invest in KURE Through Your Broker

You are now leaving KraneShares.com. Hyperlinks on these websites are provided as a convenience and we disclaim any responsibility for information, services or products found on the websites linked hereto.